Wellcome-248u en es it fr

Wellcome-248u Brand names, Wellcome-248u Analogs

Wellcome-248u Brand Names Mixture

  • Zovirax Injection (Zovirax sodium)

Wellcome-248u Chemical_Formula


Wellcome-248u RX_link


Wellcome-248u fda sheet

Wellcome-248u FDA

Wellcome-248u msds (material safety sheet)

Wellcome-248u MSDS

Wellcome-248u Synthesis Reference

H. Matsumoto et al., Chem. Pharm. Bull. 35, 1153 (1988)

Wellcome-248u Molecular Weight

225.205 g/mol

Wellcome-248u Melting Point

256.5 - 257 oC

Wellcome-248u H2O Solubility

3.399 mg/L

Wellcome-248u State


Wellcome-248u LogP


Wellcome-248u Dosage Forms

Intravenous infusion; Capsule; Tablet; Suspension; Topical cream; Topical ointment

Wellcome-248u Indication

For the treatment and management of herpes zoster (shingles), genital herpes, and chickenpox

Wellcome-248u Pharmacology

Acyclovir is a synthetic deoxyguanosine analog and it is the prototype antiviral agent that is activated by viral thymidine kinase. The selective activity of acyclovir is due to its affinity for the thymidine kinase enzyme encoded by HSV and VZV.

Wellcome-248u Absorption

Oral: bioavailability 10 to 20%

Wellcome-248u side effects and Toxicity

Acyclovir may cause nephrotoxicity (crystallization of acyclovir within renal tubules, elevation of serum creatinine, transient), and neurotoxicity (coma, hallucinations, lethargy, seizures, tremors). Nephrotoxicity and neurotoxicity usually resolve after cessation of acyclovir therapy. However, there is no well-defined relationship between acyclovir concentrations in the blood and these adverse effects.

Wellcome-248u Patient Information

Wellcome-248u Organisms Affected

Human herpes virus